Ovagen Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Ovagen dosing — protocols, safety, and where to buy.
Dose Range
No validated human dose. Khavinson cytomax convention for oral short peptides is about 10 mg once daily in 10-day courses; research suppliers of the lyophilised synthetic EDL tripeptide list roughly 1-2 mg subcutaneously daily. These are conventions, not trial-derived figures.
Frequency
Once daily during short courses (Khavinson cytomax convention)
Cycle Length
10 consecutive days per course, repeated a few times per year with washout periods of one to three months. No trial supports any particular schedule.
Half-Life
Not established - no human or animal pharmacokinetic data have been published. As a small, unprotected tripeptide, EDL is expected to be hydrolysed by peptidases within minutes in the circulation.
Dosage Calculator
Calculate exact dosing for Ovagen.
Dosing Protocols
Beginner Ovagen notes
There is no validated human protocol for Ovagen. Everything below is community/Khavinson convention, not trial-derived, and is provided for research context only.
- Product form: oral capsule (post-Soviet cytomax style) or lyophilised synthetic EDL peptide for reconstitution. Require third-party HPLC identity/purity and a certificate of analysis.
- Convention dose: about 10 mg orally once daily, or 1-2 mg subcutaneously once daily.
- Course length: 10 consecutive days.
- Washout: at least one to three months before repeating.
- If you are exploring this in a liver/GI context: get an actual workup first - liver enzymes (ALT/AST/GGT/ALP), bilirubin, and a cause-directed evaluation (viral hepatitis serologies, alcohol history, metabolic/MASLD risk). Ovagen does not replace that.
- Stop and seek care for jaundice, dark urine, pale stools, right-upper-quadrant pain, persistent nausea or vomiting, rash, or any new significant symptom.
- Do not use it to self-treat diagnosed liver disease in place of hepatology care.
- Realistic expectation: at most subtle, non-specific effects. A 10-day peptide course does not reverse fibrosis or cure hepatitis.
Intermediate Ovagen notes (experienced short-peptide users)
Still no validated protocol - convention only.
- Dose: about 10 mg oral daily, or 1-2 mg SC daily.
- Course: 10 consecutive days, typically a few times per year.
- Rotation: Khavinson users often rotate the liver/GI peptide Livagen with other Cytomax peptides (Epithalon, Thymogen). No study establishes any rotation benefit.
- Monitoring: if used with liver/GI intent, track liver enzymes and symptoms rather than assuming benefit, and treat any abnormal result as a reason to see a clinician, not to add more peptides.
- Framing: treat Ovagen as a speculative add-on on top of evidence-based liver/GI care (address the underlying cause, diet, alcohol, weight, medications), never as the primary intervention.
- Cost reality: a year of Ovagen cycling costs more than a basic liver panel and a hepatology consult, and the consult gives you information that actually changes management.
Advanced Ovagen notes (Khavinson-style rotation)
For experienced Cytomax users only; entirely convention-based, no trial support.
- Example annual pattern:
- Days 1-10: Ovagen (EDL) about 10 mg oral or 1-2 mg SC daily.
- Then one to three months washout.
- Optionally rotate the related liver peptide Livagen or other Cytomax peptides in later blocks, each as a 10-day course separated by washouts.
- Monitoring: baseline and periodic liver panel (ALT/AST/GGT/ALP, bilirubin), plus symptom tracking. Any persistent abnormality warrants a hepatology referral.
- Base layer: the real work is the evidence-based part - treating the cause of liver or GI disease, alcohol reduction, metabolic/MASLD management, and appropriate hepatitis therapy. The peptide is an experimental ritual layered on top, not the treatment.
- Do not run Ovagen instead of, or to delay, indicated medical care for liver or GI disease.
- Realistic expectation: advanced protocols do not change the fundamental fact that there is no human efficacy evidence for Ovagen.
Commonly Stacked With
Stacking Notes
Khavinson rotation
Ovagen cycles alongside Testagen (complementary male/female reproductive pair), Epitalon, Pinealon, Thymogen, Vilon, Livagen, Bronchogen, Cardiogen, Cartalax, and Chonluten.
A female reproductive-focused rotation:
- Days 1–10: Ovagen 20 mg oral/sublingual daily
- Days 11–70: Washout
- Days 71–80: Epitalon 5–10 mg SC daily (general anti-aging, pineal modulation)
- Days 81–140: Washout
- Days 141–150: Pinealon 10 mg oral daily (hypothalamic-pituitary support)
- Days 151–210: Washout
- Days 211–220: Ovagen repeat cycle
Evidence-graded reproductive stack (preferred)
- Comprehensive endocrine assessment — first step, always.
- Lifestyle optimisation — weight, smoking, stress, sleep, exercise.
- Reproductive endocrinologist consultation if fertility concerns or severe perimenopausal symptoms.
- Hormone therapy (estradiol + progestogen) for perimenopausal symptoms when indicated and not contraindicated.
- Ovulation induction (clomiphene, letrozole) or IVF for fertility treatment as indicated.
- CoQ10 200–600 mg daily — modest mitochondrial support evidence.
- Myo-inositol 2–4 g BID — RCT evidence in PCOS.
- Vitamin D 1000–4000 IU daily.
- Omega-3 EPA/DHA 2–4 g daily.
- DHEA 25–50 mg daily in select reproductive-medicine protocols.
- Experimental bioregulators (Ovagen, Testagen, Epitalon) as tier-11 add-ons.
Stacking with hormone therapy
No documented interactions. Theoretically, Ovagen layered on top of HRT does not obviously conflict, but the combination has not been formally studied. If on HRT, continue it and add Ovagen as an experimental adjunct.
Stacking with fertility treatment
Do not run Ovagen during active IVF cycles without reproductive endocrinologist knowledge. The unvalidated mechanism could theoretically affect ovarian response, and no data exist on safety during controlled ovarian hyperstimulation.
Stacking with hormonal contraception
Continue combined hormonal contraception if prescribed for contraception. Ovagen does not affect contraceptive efficacy through any known mechanism but also has not been formally studied. Do not use Ovagen for contraception.
Stacking with supplements
Epitalon + Ovagen is the most common community pair for women focused on reproductive aging and general longevity. Safe combination from an interaction standpoint. CoQ10, myo-inositol, vitamin D, and omega-3 all layer safely with Ovagen cycles.
Stacking with DHEA
DHEA is sometimes used in reproductive medicine for diminished ovarian reserve (controversial but some evidence). Combining DHEA with Ovagen is not documented but is theoretically compatible. Do not initiate DHEA without reproductive endocrinologist involvement.
Contraindicated combinations
Do not substitute for evidence-based reproductive medicine. Do not delay fertility treatment to test Ovagen alone. Do not use in hormone-sensitive cancer without oncology approval (and in most cases, avoid entirely).
Side Effects & Safety
Contraindications
## Contraindications Because human data are absent, contraindications are precautionary. ### Avoid - **Pregnancy and breastfeeding** - no reproductive-toxicity data. - **Children and adolescents.** - **Known hypersensitivity** to Ovagen or other Khavinson peptides. - **Any unregulated or unverified product** without third-party HPLC identity/purity and endotoxin testing. ### Use only with clinician oversight - **Diagnosed liver disease** (viral hepatitis, alcohol-related or metabolic/MASLD liver disease, fibrosis or cirrhosis) - these need cause-directed medical treatment; do not substitute or delay it for Ovagen. - **Active gastrointestinal disease** under investigation. - **Significant renal or hepatic impairment.** ### Not a substitute for evaluation New or worsening liver/GI symptoms - jaundice, persistent abdominal pain, GI bleeding, unexplained weight loss - require medical evaluation, not self-treatment with an experimental peptide.
Additional Notes
Dosage Notes
There is no established human dose for Ovagen. The figures below are Khavinson/cytomax convention, not the result of any dose-ranging study.
Oral dosing
- About 10 mg once daily (the labelled capsule weight usually includes excipients; actual EDL peptide content is typically a fraction of the stated milligrams and is often undisclosed).
- 10-day courses, separated by washouts of one to three months.
Subcutaneous dosing
- 1-2 mg of reconstituted synthetic EDL peptide once daily.
- 10 consecutive days per course.
Maximum and continuous use
No maximum has been characterised, and the safety of continuous dosing is unstudied - keep to short intermittent courses.
Special populations
- Diagnosed liver or GI disease: do not self-treat in place of medical care; use only, if at all, as an adjunct discussed with a clinician.
- Renal or hepatic impairment: no dose-adjustment data; caution and clinician oversight.
- Pregnancy and breastfeeding: no reproductive-toxicity data - avoid.
- Children and adolescents: not appropriate.
Quality
Because this is an unregulated research peptide, require third-party HPLC identity/purity and endotoxin testing before any use.
Frequently Asked Questions
What is the recommended Ovagen dosage?
The typical dose range for Ovagen is No validated human dose. Khavinson cytomax convention for oral short peptides is about 10 mg once daily in 10-day courses; research suppliers of the lyophilised synthetic EDL tripeptide list roughly 1-2 mg subcutaneously daily. These are conventions, not trial-derived figures.. It is usually administered Once daily during short courses (Khavinson cytomax convention). Always start with the lowest effective dose.
How often should I take Ovagen?
Once daily during short courses (Khavinson cytomax convention)
Does Ovagen need to be cycled?
Yes, typical cycle length is 10 consecutive days per course, repeated a few times per year with washout periods of one to three months. No trial supports any particular schedule..
What are Ovagen side effects?
## Side Effects and Safety Reliable human safety data for Ovagen do not exist. The Khavinson short-peptide class is generally described as low-toxicity in Russian preclinical work, but that is not the same as demonstrated human safety. ### What limited reports suggest - The related short peptides have been described as low-toxicity in animal and small Russian human observations, with occasional mild, self-limited effects (for example mild GI upset, headache, injection-site reactions with the SC form, or rare rash/hypersensitivity). - No serious adverse events specific to Ovagen have been documented - but this reflects an almost complete absence of formal pharmacovigilance, not a proven clean record. ### Real limitations - No controlled human safety study, no long-term data, and no drug-interaction studies. - Product quality is the most practical hazard: unregulated peptides can be mislabelled, underdosed, or contaminated with endotoxin. Require third-party HPLC and endotoxin testing. ### When to stop and seek care Jaundice (yellowing of skin or eyes), dark urine, pale stools, persistent right-upper-quadrant pain, persistent nausea or vomiting, severe rash, swelling, or difficulty breathing warrant stopping and prompt medical evaluation. ### Overall Treat Ovagen as experimental, with an essentially uncharacterised human safety profile. The mild reputation of the peptide class should not be read as evidence that Ovagen is safe.
Where can I buy Ovagen?
Visit our vendor directory to find trusted sources for Ovagen.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.